Ray Therapeutics closes oversubscribed $125M Series B for vision restoration

What's the deal? Ray Therapeutics, a Berkeley-based clinical-stage biopharmaceutical company developing optogenetic gene therapies to restore vision, has closed an upsized and oversubscribed $125M Series B. The round was led by Janus Henderson Investors, with new investors InvusDealroom has a profile for this one. Try Dealroom →, Franklin TempletonDealroom has a profile for this one. Try Dealroom →, Adage Capital ManagementDealroom has a profile for this one. Try Dealroom →, and Marshall WaceDealroom has a profile for this one. Try Dealroom →.

Existing investors Novo HoldingsDealroom has a profile for this one. Try Dealroom →, Deerfield ManagementDealroom has a profile for this one. Try Dealroom →, Norwest, PlatanusDealroom has a profile for this one. Try Dealroom →, and MRL Ventures FundDealroom has a profile for this one. Try Dealroom → also participated. Founding investor 4BIO CapitalDealroom has a profile for this one. Try Dealroom →, which led the seed round in 2021, continued its support.

Why now? The financing follows Ray Therapeutics' receipt of Regenerative Medicine Advanced Therapy (RMAT) Designation from the US Food and Drug AdministrationDealroom has a profile for this one. Try Dealroom → for its lead programme, RTx-015, for the treatment of retinitis pigmentosa (RP). RMAT designation offers accelerated regulatory pathways, including priority review and potential rolling submission.

Proceeds will fund two clinical-stage programmes: RTx-015 for RP and RTx-021 for macular diseases including Stargardt disease and geographic atrophy age-related macular degeneration (AMD). The company's technology uses bioengineered light-sensitive proteins to reprogram retinal cells, restoring visual function rather than merely slowing disease progression.

What could go wrong? Gene therapy remains technically challenging and commercially unproven at scale. Optogenetics in humans is still early — while the science is compelling, translating preclinical results into durable clinical outcomes is the central risk. Regulatory timelines for gene therapies are often longer than expected, and manufacturing at commercial scale has tripped up other cell and gene therapy companies.

The market for inherited retinal diseases is also small. Scaling beyond rare indications into larger populations like geographic atrophy AMD will be critical to justifying the investment.

The signal: The round's oversubscription and upsizing suggest strong institutional conviction in optogenetics as a therapeutic modality. The investor mix — blending specialist biotech VCs with large crossover funds like Janus Henderson, Franklin TempletonDealroom has a profile for this one. Try Dealroom →, and Marshall WaceDealroom has a profile for this one. Try Dealroom → — points to a company being positioned for a potential public market transition.

Sources:
Fierce Biotech
Business Insider
FinSMEs
4BIO Capital
BusinessWire
Ray Therapeutics, LinkedIn post

Image credit:
Ray Therapeutics

J.V.